Cargando…

Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats

The objective of this study was to develop a non-linear mixed-effects (NLME) model to describe the disposition kinetics of vitacoxib in cats following intravenous (I.V) and oral (P.O) (single and multiple) dosing. Data from six consecutive studies with 16 healthy neutered domestic short hair cats we...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jianzhong, Schneider, Benjamin K., Xiao, Hongzhi, Qiu, Jicheng, Gong, Xiaohui, Seo, Yeon-Jung, Li, Jing, Mochel, Jonathan P., Cao, Xingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546276/
https://www.ncbi.nlm.nih.gov/pubmed/33102567
http://dx.doi.org/10.3389/fvets.2020.554033
_version_ 1783592198513623040
author Wang, Jianzhong
Schneider, Benjamin K.
Xiao, Hongzhi
Qiu, Jicheng
Gong, Xiaohui
Seo, Yeon-Jung
Li, Jing
Mochel, Jonathan P.
Cao, Xingyuan
author_facet Wang, Jianzhong
Schneider, Benjamin K.
Xiao, Hongzhi
Qiu, Jicheng
Gong, Xiaohui
Seo, Yeon-Jung
Li, Jing
Mochel, Jonathan P.
Cao, Xingyuan
author_sort Wang, Jianzhong
collection PubMed
description The objective of this study was to develop a non-linear mixed-effects (NLME) model to describe the disposition kinetics of vitacoxib in cats following intravenous (I.V) and oral (P.O) (single and multiple) dosing. Data from six consecutive studies with 16 healthy neutered domestic short hair cats were pooled together to build a pharmacokinetic (PK) model using NLME. Population PK parameters were estimated using the stochastic approximation expectation maximization (SAEM) algorithm implemented in Monolix 2019R2. A two-compartment mammillary disposition model with simultaneous zero- and first-order absorption best described the PK of vitacoxib in plasma after oral dosing. The systemic CL of vitacoxib was found to be low (110 ml/h), with a steady-state volume of distribution (VSS) of 3.42 L in cats. Results from the automated covariate search in Monolix 2019R2 showed that bodyweight had a significant effect on the central volume of distribution of vitacoxib. Lastly, using Monte Carlo simulations, we investigated the time course of several dosages of vitacoxib from 0.01 to 8 mg/kg. Using this simulation set, we found a range of reasonable dosages that produce therapeutic plasma concentrations of vitacoxib for 24 h or more in cats.
format Online
Article
Text
id pubmed-7546276
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75462762020-10-22 Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats Wang, Jianzhong Schneider, Benjamin K. Xiao, Hongzhi Qiu, Jicheng Gong, Xiaohui Seo, Yeon-Jung Li, Jing Mochel, Jonathan P. Cao, Xingyuan Front Vet Sci Veterinary Science The objective of this study was to develop a non-linear mixed-effects (NLME) model to describe the disposition kinetics of vitacoxib in cats following intravenous (I.V) and oral (P.O) (single and multiple) dosing. Data from six consecutive studies with 16 healthy neutered domestic short hair cats were pooled together to build a pharmacokinetic (PK) model using NLME. Population PK parameters were estimated using the stochastic approximation expectation maximization (SAEM) algorithm implemented in Monolix 2019R2. A two-compartment mammillary disposition model with simultaneous zero- and first-order absorption best described the PK of vitacoxib in plasma after oral dosing. The systemic CL of vitacoxib was found to be low (110 ml/h), with a steady-state volume of distribution (VSS) of 3.42 L in cats. Results from the automated covariate search in Monolix 2019R2 showed that bodyweight had a significant effect on the central volume of distribution of vitacoxib. Lastly, using Monte Carlo simulations, we investigated the time course of several dosages of vitacoxib from 0.01 to 8 mg/kg. Using this simulation set, we found a range of reasonable dosages that produce therapeutic plasma concentrations of vitacoxib for 24 h or more in cats. Frontiers Media S.A. 2020-09-24 /pmc/articles/PMC7546276/ /pubmed/33102567 http://dx.doi.org/10.3389/fvets.2020.554033 Text en Copyright © 2020 Wang, Schneider, Xiao, Qiu, Gong, Seo, Li, Mochel and Cao. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Wang, Jianzhong
Schneider, Benjamin K.
Xiao, Hongzhi
Qiu, Jicheng
Gong, Xiaohui
Seo, Yeon-Jung
Li, Jing
Mochel, Jonathan P.
Cao, Xingyuan
Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats
title Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats
title_full Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats
title_fullStr Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats
title_full_unstemmed Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats
title_short Non-Linear Mixed-Effects Pharmacokinetic Modeling of the Novel COX-2 Selective Inhibitor Vitacoxib in Cats
title_sort non-linear mixed-effects pharmacokinetic modeling of the novel cox-2 selective inhibitor vitacoxib in cats
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546276/
https://www.ncbi.nlm.nih.gov/pubmed/33102567
http://dx.doi.org/10.3389/fvets.2020.554033
work_keys_str_mv AT wangjianzhong nonlinearmixedeffectspharmacokineticmodelingofthenovelcox2selectiveinhibitorvitacoxibincats
AT schneiderbenjamink nonlinearmixedeffectspharmacokineticmodelingofthenovelcox2selectiveinhibitorvitacoxibincats
AT xiaohongzhi nonlinearmixedeffectspharmacokineticmodelingofthenovelcox2selectiveinhibitorvitacoxibincats
AT qiujicheng nonlinearmixedeffectspharmacokineticmodelingofthenovelcox2selectiveinhibitorvitacoxibincats
AT gongxiaohui nonlinearmixedeffectspharmacokineticmodelingofthenovelcox2selectiveinhibitorvitacoxibincats
AT seoyeonjung nonlinearmixedeffectspharmacokineticmodelingofthenovelcox2selectiveinhibitorvitacoxibincats
AT lijing nonlinearmixedeffectspharmacokineticmodelingofthenovelcox2selectiveinhibitorvitacoxibincats
AT mocheljonathanp nonlinearmixedeffectspharmacokineticmodelingofthenovelcox2selectiveinhibitorvitacoxibincats
AT caoxingyuan nonlinearmixedeffectspharmacokineticmodelingofthenovelcox2selectiveinhibitorvitacoxibincats